ERAS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Erasca Inc (ERAS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the technical indicators show some bullish momentum, the recent negative sentiment from Revolution Medicines' trial success, insider selling, and weak financial performance make it prudent to hold off on investing in this stock right now.
The MACD is positive and expanding, indicating bullish momentum. The RSI is neutral at 69.879, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above its pivot point of 16.943, with resistance levels at 19.021 and 20.305.
Analysts maintain a generally positive outlook with multiple price target increases, including JPMorgan's $25 target and Guggenheim's $20 target. The company's RAS inhibitor portfolio has potential for differentiation and a large addressable market.
Revolution Medicines' positive trial results have negatively impacted Erasca's market outlook, causing a 7% drop in share price. Insiders have significantly increased selling activity (336.23% increase). Additionally, financial performance remains weak with negative net income and EPS.
In Q4 2025, Erasca reported no revenue growth (0% YoY) and a net income drop of -9.74% YoY to -$29.09M. EPS also declined by -9.09% YoY to -0.1.
Analysts maintain a positive stance with multiple Buy ratings and price target increases. However, recent developments, including Revolution Medicines' trial success, have tempered market expectations for Erasca in the short term.
